Search

Displaying results 6271 - 6280 of 7479 in total
  1. Drug

    8-azaguanine

    go.drugbank.com/drugs/DB01667
    Experimental

    It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

  2. Drug

    N-Acetyl-glucosamine thiazoline

    go.drugbank.com/drugs/DB03747
    Experimental

    N-Acetyl-glucosamine thiazoline (NAG-thiazoline) is an analog of the oxazolinium bicyclic intermediate leading from N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid.

  3. Drug

    Hygromycin B

    go.drugbank.com/drugs/DB11520
    ExperimentalVet approved

    Hygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus which kills bacteria, fungi and higher eukaryotic cells by inhibiting protein synthesis.

  4. Drug

    Cadmium

    go.drugbank.com/drugs/DB14085
    Experimental

    An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.

  5. Drug

    OCU400

    go.drugbank.com/drugs/DB18277
    Investigational

    OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).

  6. Drug

    IFx-Hu2.0

    go.drugbank.com/drugs/DB18396
    Investigational

    IFx-Hu2.0 is an investigational cancer vaccine. It is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.

  7. Drug

    NDX-3315

    go.drugbank.com/drugs/DB18671
    Investigational

    NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].

  8. Drug

    Olvimulogene nanivacirepvec

    go.drugbank.com/drugs/DB16268
    Investigational

    Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).

  9. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  10. Drug

    Altanserin

    go.drugbank.com/drugs/DB19972
    Investigational

    Altanserin has a monoisotopic molecular weight of 411.14 Da.